Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
NCT00310635
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
241
Enrollment
INDUSTRY
Sponsor class
Conditions
Meningococcal Infection
Interventions
BIOLOGICAL:
Meningococcal C conjugate vaccine
Sponsor
Novartis
Collaborators
[object Object]